

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below. **02120** **574430**

Licensee

In accordance with the application dated

February 4, 2011,

3. License number 21-00258-06 is renewed in its entirety to read as follows:

4. Expiration date **July 31, 2021**

5. Docket No. 030-01990

Reference No.

1. Allegiance Health

2. 205 N. East Avenue
Jackson, MI 49201

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material permitted by 10 CFR 35.100

A. Any

A. As needed

B. Any byproduct material permitted by 10 CFR 35.200

B. Any

B. As needed

C. Any byproduct material permitted by 10 CFR 35.300

C. Any

C. 1 curie

D. Any byproduct material permitted by 10 CFR 35.400

D. Sealed Sources (Medi-Physics, Inc. or Amersham Health Models 6711 (OncoSeed™), 6733 (EchoSeed™), 6735, Best Medical International, Inc., Model 2301, North American Scientific, Inc., Model MED3631, IsoAid L.L.C. Model IAI-125A (Advantage™ I-125), and Bard Brachytherapy, Inc., STM 1251)

D. 2 curies

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study, imaging and localization study, or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

21-00258-06

Docket or Reference Number

030-01990

Amendment No. 56

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 205 N. East Avenue, Jackson, Michigan and Paul Tejada Center, 1102 E. Michigan Avenue, Jackson, Michigan.
11. The Radiation Safety Officer for this license is Samir Parikh, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Piyashbhai Chaturbhai Patel, M.D.

10 CFR 35.100, 35.200, and 35.300.

Sadasiva T. Reddy, M.D.

10 CFR 35.100, 35.200, and 35.300.

Libby Anderson, M.D.

10 CFR 35.100, 35.200, and 35.300.

David A. Williamson, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of 33 millicuries or less of sodium iodide I-131).

Mohammad Asad, M.D.

10 CFR 35.100 and 35.200.

James Heisel, M.D.

10 CFR 35.100, 35.200, and 35.300.

Renuka M. Patel, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 for imaging and localization studies).

Bhaskar Shenai, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of 33 millicuries or less of sodium iodide I-131).

Samir Parikh, M.D.

10 CFR 35.100 and 35.200.

Patrick W. McLaughlin, M.D.

10 CFR 35.400.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
21-00258-06Docket or Reference Number
030-01990

Amendment No. 56

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated February 4, 2001; and

B. Email correspondence dated June 30, 2011, and July 19, 2011.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 05 2011

By



Toye L. Simmons
Materials Licensing Branch
Region III